Xi Zhang, Aparna Gunda, Elma Meershoek-Klein Kranenbarg, Gerrit-Jan Liefers, Badada Ananthamurthy Savitha, Payal Shrivastava, Chandra Prakash Vijay Kumar Serkad, Taranjot Kaur, Mallikarjuna Siraganahalli Eshwaraiah, Rob A E M Tollenaar, Cornelis J H van de Velde, Caroline M J Seynaeve, Manjiri Bakre, Peter J K Kuppen
BACKGROUND: Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III trial that randomized 9776 women for the use of hormonal therapy. Of these 2754 were Dutch patients. The current study aims for the first time to correlate the ten-year clinical outcomes with predictions by CanAssist Breast (CAB)-a prognostic test developed in South East Asia, on a Dutch sub-cohort that participated in the TEAM...
April 14, 2023: Breast Cancer Research: BCR